HomeAI · summaries
Storia in 3 fonti
Agios’ second shot at sickle cell disease falls short
Agios' PK activator tebapivat looked no better than the first-generation agents in sickle cell disease, although it's awaiting approval for mitapivat in the same condition.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Agios scraps sickle cell drug
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
- ·
endpoints.news
Agios’ second shot at sickle cell disease falls short
Agios' PK activator tebapivat looked no better than the first-generation agents in sickle cell disease, although it's awaiting approval for mitapivat in the same condition.
- ·
benzinga.com
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Agios Pharmaceuticals (NASDAQ:AGIO)
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.